1. Home
  2. FOA vs SGMT Comparison

FOA vs SGMT Comparison

Compare FOA & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finance of America Companies Inc.

FOA

Finance of America Companies Inc.

HOLD

Current Price

$19.70

Market Cap

177.1M

Sector

Finance

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.76

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOA
SGMT
Founded
2013
2006
Country
United States
United States
Employees
784
N/A
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
177.1M
169.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FOA
SGMT
Price
$19.70
$6.76
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$26.00
$26.13
AVG Volume (30 Days)
46.7K
742.9K
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,000,000.00
Revenue This Year
$0.58
N/A
Revenue Next Year
$6.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.77
$4.50
52 Week High
$29.58
$11.41

Technical Indicators

Market Signals
Indicator
FOA
SGMT
Relative Strength Index (RSI) 48.96 46.60
Support Level $19.00 $6.33
Resistance Level $20.17 $7.39
Average True Range (ATR) 0.80 0.39
MACD 0.01 -0.08
Stochastic Oscillator 67.37 33.91

Price Performance

Historical Comparison
FOA
SGMT

About FOA Finance of America Companies Inc.

Finance of America Companies Inc provides home equity-based financing solutions for modern retirement and offers capital markets and portfolio management capabilities to optimize loan distribution to investors. The Company operates through two segments: Retirement Solutions and Portfolio Management. The Retirement Solutions segment handles loan origination, including HECM and non-agency reverse mortgage loans, generating revenue from origination fees and initial gains, with loans transferred to the Portfolio Management segment. The Portfolio Management segment, which generates the majority of revenue, provides securitization, loan sales, risk management, and asset management services, and earns revenue from net interest income, fair value changes, and servicing-related income.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: